Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for rare cancers: drug combo shows promise in shrinking tumors

NCT ID NCT01396408

First seen Apr 20, 2026 · Last updated May 01, 2026 · Updated 4 times

Summary

This study tests two drugs, sunitinib and temsirolimus, in 137 people with rare advanced cancers that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants must have one of several rare tumor types, such as certain sarcomas or thyroid cancers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED RARE TUMOURS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Allan Blair Cancer Centre

    Regina, Saskatchewan, S4T 7T1, Canada

  • BCCA - Cancer Centre for the Southern Interior

    Kelowna, British Columbia, V1Y 5L3, Canada

  • BCCA - Vancouver Cancer Centre

    Vancouver, British Columbia, V5Z 4E6, Canada

  • CHU Sainte-Justine

    Montreal, Quebec, H3T 1C5, Canada

  • CHUM - Hopital Notre-Dame

    Montreal, Quebec, H2L 4M1, Canada

  • CancerCare Manitoba

    Winnipeg, Manitoba, R3E 0V9, Canada

  • Cross Cancer Institute

    Edmonton, Alberta, T6G 1Z2, Canada

  • Hospital for Sick Children

    Toronto, Ontario, M5G 1X8, Canada

  • Izaak Walton Killam (IWK) Health Centre

    Halifax, Nova Scotia, B3K 6R8, Canada

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, L8V 5C2, Canada

  • London Regional Cancer Program

    London, Ontario, N6A 4L6, Canada

  • McGill University - Dept. Oncology

    Montreal, Quebec, H2W 1S6, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, K1H 8L6, Canada

  • QEII Health Sciences Centre

    Halifax, Nova Scotia, B3H 1V7, Canada

  • Saskatoon Cancer Centre

    Saskatoon, Saskatchewan, S7N 4H4, Canada

  • Tom Baker Cancer Centre

    Calgary, Alberta, T2N 4N2, Canada

  • Univ. Health Network-Princess Margaret Hospital

    Toronto, Ontario, M5G 2M9, Canada

Conditions

Explore the condition pages connected to this study.